Pierce David A's Form 4 filing
Boston Scientific Corp (BSX) · filed Dec 21, 2021
- Accession no.
- 0001225208-21-015180
- Filed
- Dec 21, 2021
- Trade date
- Dec 20, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.99M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pierce David ACIK 0001529751 | Officer (EVP Pres MedSurg) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 20, 2021 | Common Stock | MOption exerciseAcquired | +42,934 | $7.39 | +$317,282.26 | 44,991 | Direct | |
| Dec 20, 2021 | Common Stock | MOption exerciseAcquired | +4,997 | $6.28 | +$31,381.16 | 49,988 | Direct | |
| Dec 20, 2021 | Common Stock | SSaleDisposed | −49,988 | $39.90F2 | −$1,994,521.2 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 20, 2021 | Common Stock | MOption exerciseDisposed | −4,997 | $0.00 | $0 | 0 | Direct | |
| Dec 20, 2021 | Common Stock | MOption exerciseDisposed | −42,934 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $39.47 to $40.31, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.